about
Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors.Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acidsStructure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors3'-Azido-3'-deoxythymidine drug resistance mutations in HIV-1 reverse transcriptase can induce long range conformational changesIn vitro anti-human immunodeficiency virus activities of Z- and E-methylenecyclopropane nucleoside analogues and their phosphoro-L-alaninate diestersMechanism of inhibition of the human immunodeficiency virus type 1 reverse transcriptase by d4TTP: an equivalent incorporation efficiency relative to the natural substrate dTTPIn vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidineResistance pattern of human immunodeficiency virus type 1 reverse transcriptase to quinoxaline S-2720Action of uracil analogs on human immunodeficiency virus type 1 and its reverse transcriptaseDifferential activities of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives against different human immunodeficiency virus type 1 mutant strainsNovel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolatesResistance of human immunodeficiency virus type 1 to acyclic 6-phenylselenenyl- and 6-phenylthiopyrimidinesHomologues of isomeric dideoxynucleosides as potential antiviral agents: synthesis of isodideoxynucleosides with a furanethanol sugar moietyDevelopment of a functional backbone cyclic mimetic of the HIV-1 Tat arginine-rich motifEvaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replicationIdentification of novel thiocarboxanilide derivatives that suppress a variety of drug-resistant mutant human immunodeficiency virus type 1 strains at a potency similar to that for wild-type virusCharacteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors.A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at positions 74 and 75 via the template primerSubunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase.Construction and characterization of a temperature-sensitive human immunodeficiency virus type 1 reverse transcriptase mutantPharmacokinetics of the antiviral agent beta-L-3'-fluoro-2',3'-didehydro-2',3'-dideoxycytidine in rhesus monkeys.Steered molecular dynamics simulation on the binding of NNRTI to HIV-1 RT.Non-nucleoside reverse transcriptase inhibitors: perspectives on novel therapeutic compounds and strategies for the treatment of HIV infection.Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides.Antiviral activity and pharmacokinetics of 1-(2,3-dideoxy-2-fluoro-beta-L-glyceropent-2-enofuranosyl)cytosine.Analysis of mutations at positions 115 and 116 in the dNTP binding site of HIV-1 reverse transcriptase.Antiviral activities of isometric dideoxynucleosides of D- and L-related stereochemistry.Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1.Antiviral, metabolic, and pharmacokinetic properties of the isomeric dideoxynucleoside 4(S)-(6-amino-9H-purin-9-yl)tetrahydro-2(S)-furanmethanol.Antiviral therapy for human immunodeficiency virus infectionsIn search of a selective antiviral chemotherapy.Subunit-specific mutagenesis of the cysteine 280 residue of the reverse transcriptase of human immunodeficiency virus type 1: effects on sensitivity to a specific inhibitor of the RNase H activity.Prioritizing Hits with Appropriate Trade-Offs Between HIV-1 Reverse Transcriptase Inhibitory Efficacy and MT4 Blood Cells Toxicity Through Desirability-Based Multiobjective Optimization and Ranking.Optimization of allele-specific PCR using patient-specific HIV consensus sequences for primer designConcomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors.Human recombinant antibody fragments neutralizing human immunodeficiency virus type 1 reverse transcriptase provide an experimental basis for the structural classification of the DNA polymerase family.Fluorescent HIV-1 Dimerization Initiation Site: design, properties, and use for ligand discoveryNovel 4'-substituted stavudine analog with improved anti-human immunodeficiency virus activity and decreased cytotoxicity.High-affinity interaction of human immunodeficiency virus type-1 reverse transcriptase with partially complementary primers.
P2860
Q24540388-43361733-7B30-44C3-97CB-E242C0AF9DF3Q24682078-6FAF5C9A-CF0C-4F8E-AF80-1D5D5C9A261EQ27729437-5B24953F-A6DF-4726-8A03-BF156F7F5EB7Q27764900-378FA72C-A71F-44A6-888F-19263B2D90D9Q28343355-9F8A3EB2-FDDF-4591-8355-676DFD4234F1Q28343830-E31D4CDC-710E-4EA6-97A3-E0E18B39F923Q28344355-D4F36EBF-789B-4949-A88A-2A996A522380Q28367603-1567CA74-E949-4CE5-B43B-A20B4251AECFQ28367677-F73BB191-6840-4AC4-B328-A0E108C1530DQ28367707-B4589E92-D065-4CBF-9C34-AC00DB80EA0BQ28367722-D448E5E4-DBBA-4248-B310-C9D669F1CF34Q28368381-0423CBBD-1CA3-484E-AF95-5868E53B2766Q28375823-A38F2F72-37D7-43D7-AEF3-CB57932B7F99Q28376787-9FA49916-E9E2-4110-B098-519D3DA494F1Q28378991-0B1E284B-83D6-4C4A-86B8-FD5F5D6D7CC5Q28379002-D6902FBB-3FD6-4866-B796-538FC69A5C3BQ28379192-3CCA07AE-F559-4885-90FB-B4F4F11F6F19Q32157822-18AE9807-2C76-4EF5-A615-BAF60AF9628DQ33690164-10375ADD-9D36-4556-9B3B-BA1FE03F5C3AQ33757596-D46060EF-B392-498E-B24E-B22A3EC53A4AQ33782366-E29FE118-5997-416F-8EFD-46E75CCDAE62Q33804880-14FCD149-A77F-47DC-9FB4-F516C194516DQ34181367-57E50BB5-3666-4F46-AD83-62CE0724AD66Q34481618-FA5A6D77-B0C1-4829-A28C-787653C281B2Q34594711-D576AC98-12A7-40EA-8AE9-D79FCE5575C0Q35013945-73B6D91A-DB2E-4AAC-8C22-EE6C12FB46DAQ35104511-57A5FB8E-7DBB-4845-B9FA-FBAEEDE82E09Q35114114-53BD5C67-46E4-4EBB-9542-765A6A275BD4Q35116619-961F5D65-C47C-4AEE-A18F-872EBDBA2C1EQ35118261-A45569DE-E2F9-48B1-AECC-A3D534D85123Q35366050-524C6A45-930A-47F2-A181-01AD1A670F51Q35375912-BB89CA05-66B4-4718-AC18-B1AB2F0D96CBQ35889066-FBB5EA48-26BE-496B-AE8F-BABD701AF177Q36087023-4B175AE1-36F4-4311-95DF-53FBB1957EECQ36525986-C779C843-740F-4CA8-9745-8185D744BE19Q36689086-A8435F5A-EBD6-4387-A459-8C84FF9E8578Q36829686-45B2E941-7CE6-4BD7-AC48-D8B534680020Q36852633-AF3F457A-75DA-4B8B-A8FF-7E43BFDB0D9CQ37734538-06DC4FEE-092A-44C8-A980-F12144E6E83DQ38289776-F331FF9B-E91C-4EA3-BD11-AA98ED46AFBB
P2860
description
1994 nî lūn-bûn
@nan
1994 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
HIV resistance to reverse transcriptase inhibitors.
@ast
HIV resistance to reverse transcriptase inhibitors.
@en
HIV resistance to reverse transcriptase inhibitors.
@nl
type
label
HIV resistance to reverse transcriptase inhibitors.
@ast
HIV resistance to reverse transcriptase inhibitors.
@en
HIV resistance to reverse transcriptase inhibitors.
@nl
prefLabel
HIV resistance to reverse transcriptase inhibitors.
@ast
HIV resistance to reverse transcriptase inhibitors.
@en
HIV resistance to reverse transcriptase inhibitors.
@nl
P1476
HIV resistance to reverse transcriptase inhibitors.
@en
P2093
De Clercq E
P304
P356
10.1016/0006-2952(94)90001-9
P407
P577
1994-01-01T00:00:00Z